AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: A phase 2/3 randomized, placebo-controlled, observer-blinded trial

Journal of Infectious Diseases

Volumn 211, Issue 5, 2015, Pages 801-810

  Kosalaraksa, Pope ^a   Jeanfreau, Robert ^b   Frenette, Louise ^c   Drame, Mamadou ^d   Madariaga, Miguel ^d,f   Innis, Bruce L ^d   Godeaux, Olivier ^e   Izurieta, Patricia ^e   Vaughn, David W ^e  

^a KHON KAEN UNIVERSITY   (Thailand)

^b Benchmark Research   (United States)

^c QT Research   (Canada)

^d GLAXOSMITHKLINE   (United States)

^e GSK   (Belgium)

^f Naples Community Hospital Healthcare System   (United States)

Author keywords

Adjuvant; AS03B; H5N1; Influenza vaccine; Pandemic; Prepandrix

Indexed keywords

ADJUVANT; AS03B; INFLUENZA VACCINE; PLACEBO; UNCLASSIFIED DRUG; ALPHA TOCOPHEROL; ASO3B ADJUVANT; DRUG COMBINATION; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ADJUVANT THERAPY; ADOLESCENT; AGE DISTRIBUTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; CHILD; CONFERENCE PAPER; CONTROLLED STUDY; CONVULSION; COUGHING; DEHYDRATION; DROWSINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; HYPERHIDROSIS; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INGUINAL HERNIA; INJECTION SITE PAIN; IRRITABILITY; LOSS OF APPETITE; MALE; MONONUCLEOSIS; MOOD DISORDER; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; OTITIS MEDIA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHIVERING; SPONTANEOUS ABORTION; UPPER RESPIRATORY TRACT INFECTION; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; VACCINATION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PLACEBOS; POLYSORBATES; SINGLE-BLIND METHOD; SQUALENE; TREATMENT OUTCOME; VACCINATION; VACCINES, INACTIVATED;

EID: 84939621841     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu548     Document Type: Conference Paper

References (35)

1. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. 2014. http://www.who.int/influenza/human-animal-interface/EN-GIP-20140124 CumulativeNumberH5N1cases.pdf?ua=1. Accessed 26 August 2014.
2. Oner AF, Dogan N, Gasimov V, et al. H5N1 avian influenza in children. Clin Infect Dis 2012;55:26-32.
3. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009;361:1935-44.
4. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010;375:1100-8.
5. Food and Drug Administration. FDA approves first adjuvanted vaccine for prevention of H5N1 avian influenza. 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376444.htm. Accessed 26 August 2014.
6. US Food and Drug Administration. H5N1 influenza virus vaccine, manufactured by Sanofi Pasteur, Inc. Questions and answers. 2013. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/Questionsabout Vaccines/ucm080753.htm. Accessed 26 August 2014.
7. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009;9:1057-71.
8. Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive im-munogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010;201:1644-53.
9. Díez-Domingo J, Garcés-Sanchez M, Baldó J-M, et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (clade 1) AS03-adjuvanted pre-pandemic candidate influenza vaccines in children aged 3 to 9 years: A Phase II, randomized, open, controlled study. Pediatr Infect Dis J 2010;29:e35-46.
10. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immu-nogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004;103:163-71.
11. Kendal AP, Pereira MS, Skehel JJ. Hemagglutination inhibition. Concepts and procedures for laboratory-based influenza surveillance. Atlanta: Centers for Disease Control and Prevention and Pan-American Health Organization, 1982:B17-35.
12. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-43.
13. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythro-cytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004;103:91-5.
14. Reed L, Muench H. A simple method of estimating fifty percent end-points. Am J Hyg 1938;27:493-7.
15. Michael Marcy S, Kohl KS, Dagan R, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004;22:551-6.
16. Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. 2007. http://www.fda.gov/BiologicsBlood Vaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074786.htm. Accessed 26 August 2014.
17. European Committee for Proprietary Medicinal Products, European Medicines Agency. CHMP recommendations for the pharmacovigi-lance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/Report/2010/01/WC500051739.pdf. Accessed 26 August 2014.
18. Leroux-Roels I, Roman F, Forgus S, et al. Priming with AS03 (A)-adju-vanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study. Vaccine 2010;28:849-57.
19. Nolan T, Richmond PC, Formica NT, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008;26:6383-91.
20. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010;375:41-8.
21. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03 (A)-Ad-juvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age. Clin Infect Dis 2010;51:668-77.
22. Pyhala R, Kumpulainen V, Alanko S, Forsten T. HI antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in 1990-1992. Vaccine 1994;12:947-52.
23. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008;3:e1665.
24. Rumke HC, Bayas JM, De Juanes JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008;26:2378-88.
25. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012;7:e33536.
26. Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013;346:f794.
27. Dauvilliers Y, Arnulf I, Lecendreux M, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain J Neurol 2013;136:2486-96.
28. Heier MS, Gautvik KM, Wannag E, et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 2013;14:867-71.
29. Szakács A, Darin N, Hallböök T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013;80:1315-21.
30. Wijnans L, Lecomte C, De Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A (H1N1) pdm09 pandemic and vaccination campaigns. Vaccine 2013;31:1246-54.
31. Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010. Final Report of National Narcolepsy Study Steering Committee. 2010. https://hpsc.ie/A-Z/Respiratory/Influenza/PandemicInfluenza/PandemicInfluenzaH1N12009/Vacci nation/File, 13379, en.pdf. Accessed 17 October 2014.
32. European Centre for Disease Control and Prevention. Narcolepsy in association with pandemic vaccination; a multi-country European epi-demiological investigation. 2012. http://www.ecdc.europa.eu/en/publications/Publications/Vaesco%20report%20FINAL%20with% 20cover.pdf. Accessed 26 August 2014.
33. National Institute for Health and Welfare. Increased risk of narcolepsy observed also among adults vaccinated with Pandemrix in Finland. 2013. http://www4.thl.fi/en-US/web/en/pressrelease?id=33516. Accessed 26 August 2014.
34. Registry study confirms increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents and shows an increased risk in young adults. Medical Products Agency, 2013. http://www.lakemedelsverket.se/english/All-news/NYHETER-2013/Registry-study-confirms-increased-risk-of-narcolepsy-after-vaccination-with-Pandemrix-in-children-and-adolescents-and-shows-an-increased-risk-in-young-adults/. Accessed 26 August 2014.
35. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011;70:410-7.